SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

BioThrax

EBS·Emergent BioSolutions Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed since 1970.
Why 4/10
BioThrax is an already-approved, marketed vaccine with no pending PDUFA date, pivotal readout, or regulatory decision in the next 12 months. The drug generates recurring government contract revenue but lacks a hard binary catalyst, capping the impact score at 4 per the rubric.
Actionable Insight NEUTRAL

BioThrax is a mature, approved product with no pending FDA catalyst. The stock's next binary event is the Q4 2026 earnings report (likely Feb 2027), where the key question is whether Anthrax MCM revenue stabilizes after the Q3 miss and whether the CYFENDUS transition cannibalizes BioThrax further. Watch for DoD contract renewals on the $21.5M BioThrax delivery order (option periods for 2027-2028).

Price Chart

Loading chart...

Executive Summary

BioThrax (Anthrax Vaccine Adsorbed) is a long-approved anthrax vaccine originally licensed in 1970 and manufactured by Emergent BioSolutions Inc. (NYSE: EBS). It is one of only two FDA-approved anthrax vaccines (alongside the company's own next-gen product CYFENDUS) and generates recurring revenue primarily through U.S. government contracts with the Department of Defense and BARDA. BioThrax is a mature, cash-generative product but faces internal cannibalization from CYFENDUS (approved 2023), which offers a shorter dosing schedule. The stock fell sharply after Q3 2026 earnings on Nov 2, 2026 (revenue down 52% YoY, guidance cut), though the Anthrax MCM segment itself grew. With no pending regulatory catalyst for BioThrax, the drug is a steady but declining contributor within a company undergoing restructuring and leadership transition.

How It Works

BioThrax is a vaccine that trains the immune system to recognize and neutralize anthrax bacteria. It contains filtered proteins from a weakened, non-infectious strain of Bacillus anthracis, along with aluminum hydroxide as an adjuvant to boost the immune response. It is given as an injection (intramuscular or subcutaneous) to prevent anthrax disease before or after exposure.

Trial Status

BioThrax is FDA-approved for pre-exposure prophylaxis (active immunization) and post-exposure prophylaxis of anthrax disease. It received a supplemental approval under the FDA Animal Rule in November 2015 for inhalational anthrax. A Phase 3 study (VELOCITY, NCT03877926) comparing AV7909/CYFENDUS to BioThrax was completed in 2020 with 3,689 participants.

The Two-Sided Case

▲ Bull Case5
BioThrax is a long-approved, sole-source biodefense vaccine for anthrax with a guaranteed government customer base (DoD, BARDA, foreign governments), providing recurring, non-discretionary revenue.
In January 2026, Emergent received a $21.5M delivery order from the U.S. Department of War for BioThrax, with option periods extending through 2028.
Anthrax MCM revenue (BioThrax + CYFENDUS + other anthrax products) increased $23.7M YoY in Q3 2026, driven by U.S. government procurement timing.
Multiple institutional investors added or doubled positions in Q2 2026, including Millennium Management (+101.5%), Goldman Sachs (+27.6%), and Federated Hermes (+82.1%).
Analyst consensus shows 5 Buy/Strong Buy ratings vs 1 Hold and 1 Sell, with a mean price target of $11 (61.5% implied upside from the $6.81 close).
▼ Bear Case5
BioThrax is being internally cannibalized by Emergent's own next-gen product CYFENDUS (approved July 2023), which uses the same active ingredient with an adjuvant for a shorter dosing schedule.
The company's Q3 2026 revenue fell 52% YoY to $110M, missing consensus of $123.2M, and full-year guidance was cut for the second time in 2026.
Emergent faces a securities fraud investigation (announced Aug 2026) and a CFO transition, adding governance risk.
Insider sales in October 2026 (director sold $126K, SVP sold $19.6K) signal limited confidence from management.
The company's net leverage increased to 2.4x from 1.9x YoY despite debt reduction, due to lower trailing EBITDA.

Upcoming Catalysts

  • Q4 2026 earnings report (expected Feb 2027) - key indicator of Anthrax MCM revenue trajectory and BioThrax contract execution
  • DoD option period decisions for the $21.5M BioThrax delivery order (2027-2028 option periods)
  • Any further BARDA or DoD contract awards for BioThrax or CYFENDUS

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Emergent BioSolutions Inc. 8-K EBS ·Originating report

Sources · 8

Hover a chip for the title
1 fda.gov2 en.wikipedia.org3 investors.emergentbiosolutions.com4 morningstar.com5 msn.com6 sec.gov7 fda.gov8 pmc.ncbi.nlm.nih.gov